Successful completion of key studies in lead up to Phase I

 Lead drug candidate EmtinB™ successfully completedin vitrogenotoxicity studies and plasma protein binding studies – key studies in finalising the neurology safety program  Completion of genotoxicity studies is another significant step in developing the safety profile of EmtinB™ prior to first-in-human studies  Plasma protein binding studies demonstrated that 98% of EmtinB™ in blood circulation